•  Summary 
  •  
  •  Actions 
  •  
  •  Committee Votes 
  •  
  •  Floor Votes 
  •  
  •  Memo 
  •  
  •  Text 
  •  
  •  LFIN 
  •  
  •  Chamber Video/Transcript 

A07245 Summary:

BILL NOA07245
 
SAME ASSAME AS S04370
 
SPONSORGottfried
 
COSPNSRMcDonald, Frontus, Barron, Englebright, Perry, Rivera JD, Griffin, Davila, Burdick, Simon, Sillitti, Barnwell, Epstein, Rosenthal L, Wallace, Lupardo, Gonzalez-Rojas
 
MLTSPNSR
 
Add Art 2-A Title IV §§282 & 283, Pub Health L
 
Relates to preserving access to affordable drugs; provides that an agreement resolving or settling, on a final or interim basis, a patent infringement claim, in connection with the sale of a pharmaceutical product, is to be presumed to have anticompetitive effects if a nonreference drug filer receives anything of value from another company asserting patent infringement and if the nonreference drug filer agrees to limit or forego research, development, manufacturing, marketing, or sales of the nonreference drug filers product for any period of time.
Go to top